These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20516140)

  • 1. Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands.
    Weltzin MM; Schulte MK
    J Pharmacol Exp Ther; 2010 Sep; 334(3):917-26. PubMed ID: 20516140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.
    Weltzin MM; Huang Y; Schulte MK
    Eur J Pharmacol; 2014 Jun; 732():159-68. PubMed ID: 22732654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric modulation of α4β2* nicotinic acetylcholine receptors: Desformylflustrabromine potentiates antiallodynic response of nicotine in a mouse model of neuropathic pain.
    Bagdas D; Ergun D; Jackson A; Toma W; Schulte MK; Damaj MI
    Eur J Pain; 2018 Jan; 22(1):84-93. PubMed ID: 28809075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric modulator Desformylflustrabromine relieves the inhibition of α2β2 and α4β2 nicotinic acetylcholine receptors by β-amyloid(1-42) peptide.
    Pandya A; Yakel JL
    J Mol Neurosci; 2011 Sep; 45(1):42-7. PubMed ID: 21424792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. des-Formylflustrabromine (dFBr): A Structure-Activity Study on Its Ability To Potentiate the Action of Acetylcholine at α4β2 Nicotinic Acetylcholine Receptors.
    Dukat M; Jain A; German N; Ferrara-Pontoriero R; Huang Y; Ma Y; Schulte MK; Glennon RA
    ACS Chem Neurosci; 2018 Dec; 9(12):2984-2996. PubMed ID: 30028943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desformylflustrabromine Modulates α4β2 Neuronal Nicotinic Acetylcholine Receptor High- and Low-Sensitivity Isoforms at Allosteric Clefts Containing the β2 Subunit.
    Weltzin MM; Schulte MK
    J Pharmacol Exp Ther; 2015 Aug; 354(2):184-94. PubMed ID: 26025967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desformylflustrabromine, a positive allosteric modulator of α4β2-containing nicotinic acetylcholine receptors, enhances cognition in rats.
    Nikiforuk A; Litwa E; Krawczyk M; Popik P; Arias H
    Pharmacol Rep; 2020 Jun; 72(3):589-599. PubMed ID: 32207091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desformylflustrabromine (dFBr), a positive allosteric modulator of the α
    DeCristofano L; Decker S; Schulte MK; Suryanarayanan A
    Alcohol; 2021 Jun; 93():35-44. PubMed ID: 33652092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.
    Hamouda AK; Wang ZJ; Stewart DS; Jain AD; Glennon RA; Cohen JB
    Mol Pharmacol; 2015 Jul; 88(1):1-11. PubMed ID: 25870334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses.
    Wang ZJ; Deba F; Mohamed TS; Chiara DC; Ramos K; Hamouda AK
    J Biol Chem; 2017 Jun; 292(24):9988-10001. PubMed ID: 28446611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deconstruction of the α4β2 nicotinic acetylcholine receptor positive allosteric modulator desformylflustrabromine.
    German N; Kim JS; Jain A; Dukat M; Pandya A; Ma Y; Weltzin M; Schulte MK; Glennon RA
    J Med Chem; 2011 Oct; 54(20):7259-67. PubMed ID: 21905680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.
    Hamouda AK; Bautista MR; Akinola LS; Alkhlaif Y; Jackson A; Carper M; Toma WB; Garai S; Chen YC; Thakur GA; Fowler CD; Damaj MI
    Neuropharmacology; 2021 Jun; 190():108568. PubMed ID: 33878302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator.
    Kim JS; Padnya A; Weltzin M; Edmonds BW; Schulte MK; Glennon RA
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4855-60. PubMed ID: 17604168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desformylflustrabromine: A Novel Positive Allosteric Modulator for beta2 Subunit Containing Nicotinic Receptor Sub-Types.
    Pandya AA
    Curr Pharm Des; 2016; 22(14):2057-63. PubMed ID: 26818864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs.
    Zwart R; van Kleef RG; Gotti C; Smulders CJ; Vijverberg HP
    J Neurochem; 2000 Dec; 75(6):2492-500. PubMed ID: 11080202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.
    Hamouda AK; Jackson A; Bagdas D; Imad Damaj M
    Nicotine Tob Res; 2018 Jun; 20(7):903-907. PubMed ID: 29059422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.
    Liu X
    Psychopharmacology (Berl); 2013 Nov; 230(2):203-13. PubMed ID: 23712602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY2087101 and dFBr share transmembrane binding sites in the (α4)3(β2)2 Nicotinic Acetylcholine Receptor.
    Deba F; Ali HI; Tairu A; Ramos K; Ali J; Hamouda AK
    Sci Rep; 2018 Jan; 8(1):1249. PubMed ID: 29352227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Administration of Desformylflustrabromine Relieves Chemically Induced Pain in CD-1 Mice.
    Weggel LA; Pandya AA
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30866543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators using the parallel oocyte electrophysiology test station.
    Malysz J; Grønlien JH; Timmermann DB; Håkerud M; Thorin-Hagene K; Ween H; Trumbull JD; Xiong Y; Briggs CA; Ahring PK; Dyhring T; Gopalakrishnan M
    Assay Drug Dev Technol; 2009 Aug; 7(4):374-90. PubMed ID: 19689206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.